Eva-Maria Jacobsen

Eva-Maria Jacobsen

Auto-generated profile, based on publicly available information

Eva-Maria Jacobsen

Department of Pediatrics and Adolescent Medicine Ulm University Medical Center Ulm Germany

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
11 October 2023 in EMBO Reports
Verified
Journal Article
Open access
VMVladimir G Magalhães
Vladimir G Magalhães
SLSören Lukassen
Sören Lukassen
MDMaike Drechsler
Maike Drechsler
JLJennifer Loske
Jennifer Loske
SBSandy Stephanie Burkart
Sandy Stephanie Burkart
Marco BinderMarco Binder
Marco Binder
The risk of developing severe COVID-19 rises dramatically with age. Schoolchildren are significantly less likely than older people to die from SARS-CoV-2 infection, but the molecular mechanisms underlying this age-dependence are unknown. In primary infections, innate immunity is critical due to the lack of immune memory. Children, in particular, have a significantly stronger interferon response due to a primed state of their airway epithelium. In single-cell transcriptomes of nasal turbinates, we find increased frequencies of immune cells and stronger cytokine-mediated interactions with epithelial cells, resulting in increased epithelial expression of viral sensors (RIG-I, MDA5) via IRF1. In vitro, adolescent peripheral blood mononuclear cells produce more cytokines, priming A549 cells for stronger interferon responses to SARS-CoV-2. Taken together, our findings suggest that increased numbers of immune cells in the airways of children and enhanced cytokine-based interactions with epithelial cells tune the setpoint of the epithelial antiviral system. Our findings shed light on the molecular basis of children's remarkable resistance to COVID-19 and may suggest a novel concept for immunoprophylactic treatments.

14 November 2023 in Journal of Experimental Medicine
Verified
Journal Article
Open access
PDF file
VLVictor G. Lui
Victor G. Lui
MHManfred Hoenig
Manfred Hoenig
BCBerenice Cabrera-Martinez
Berenice Cabrera-Martinez
RBRyan M. Baxter
Ryan M. Baxter
JGJosselyn E. Garcia-Perez
Josselyn E. Garcia-Perez
EHElena W.Y. Hsieh
Elena W.Y. Hsieh
Lymphocyte-specific protein tyrosine kinase (LCK) is essential for T cell antigen receptor (TCR)–mediated signal transduction. Here, we report two siblings homozygous for a novel LCK variant (c.1318C>T; P440S) characterized by T cell lymphopenia with skewed memory phenotype, infant-onset recurrent infections, failure to thrive, and protracted diarrhea. The patients’ T cells show residual TCR signal transduction and proliferation following anti-CD3/CD28 and phytohemagglutinin (PHA) stimulation. We demonstrate in mouse models that complete (Lck−/−) versus partial (LckP440S/P440S) loss-of-function LCK causes disease with differing phenotypes. While both Lck−/− and LckP440S/P440S mice exhibit arrested thymic T cell development and profound T cell lymphopenia, only LckP440S/P440S mice show residual T cell proliferation, cytokine production, and intestinal inflammation. Furthermore, the intestinal disease in the LckP440S/P440S mice is prevented by CD4+ T cell depletion or regulatory T cell transfer. These findings demonstrate that P440S LCK spares sufficient T cell function to allow the maturation of some conventional T cells but not regulatory T cells—leading to intestinal inflammation.

28 November 2020 in Clinical Immunology
Verified
Journal Article
Open access
CWChristine Wildermann
Christine Wildermann
MAMohammed Faraj Alosaimi
Mohammed Faraj Alosaimi
SLSophie Liebenehm
Sophie Liebenehm
EJEva-Maria Jacobsen
Eva-Maria Jacobsen
TBThomas FE Barth
Thomas FE Barth
MHManfred Hönig
Manfred Hönig
Complete remission from recurrent EBV-positive lymphoma is not mandatory before HSCT to achieve long-term cure in a patient suffering from a recently described immunodeficiency affecting the T-cell coactivation molecule 4-1BB.

3 December 2024 in Journal of Medical Virology
Verified
Journal Article
Open access
MSMaximilian Stich
Maximilian Stich
VMVladimir Gonçalves Magalhães
Vladimir Gonçalves Magalhães
FBFriederike Bürger
Friederike Bürger
SGSven F Garbade
Sven F Garbade
KJKathrin Jeltsch
Kathrin Jeltsch
BTBurkhard Tönshoff
Burkhard Tönshoff
The pivotal role of the cell entry receptor ACE2 for SARS‐CoV‐2 infection is well‐established. When ACE2 is shed from cell surface into plasma as soluble ACE2 (sACE2), it can effectively neutralize SARS‐CoV‐2. This longitudinal prospective cohort study analyzed sACE2 activity in 1192 participants, aged 4 months to 81 years, 3 and 12 months after SARS‐CoV‐2 household exposure. Following SARS‐CoV‐2 exposure, participants exhibited significantly elevated sACE2 activity, irrespective of confirmed infection, with the highest levels observed in exposed children. Longitudinal analysis revealed a decline in sACE2 levels over time, reaching levels comparable to age‐ and sex‐matched pre‐pandemic controls. An increase in sACE2 activity was also confirmed in vitro in Calu‐3 (human lung) cells within hours of SARS‐CoV‐2 exposure, providing a direct link between SARS‐CoV‐2 exposure and elevated sACE2. This study, therefore, challenges the dichotomy of categorizing SARS‐CoV‐2 exposed participants as infected or not infected solely on currently established diagnostic assays. It demonstrates lasting host responses independent of B‐ and T‐cell memory and may help to keep SARS‐CoV‐2 infections in balance and contribute to successful virus clearance in children and adults lacking humoral and cellular immune responses following SARS‐CoV‐2 exposure.Trial Registration: German Registry for Clinical Studies; Identifier: D 00021521.